Wyatt Sargent is an 18-month-old Superhero. He was diagnosed with ATRT, a rare aggressive childhood CNS tumor at 1 month old.

At 15 months old, he relapsed after enduring almost a year of high dose aggressive chemotherapy.

He is currently waiting on a trial to be re-opened for Tazemetostat, an EZH2 inhibitor drug known to target SMARCB1 deletion tumors, such as ATRT.

He is waiting on ONE signature from the FDA.

It has been 2 months since the FDA has had the paperwork. He has endured life-threatening complications because his body is tired and weak from the chemotherapy last year.

This drug could save his life.